NCT03073395View on ClinicalTrials.gov

Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

October 27, 2023

Study Completion Date

October 27, 2023

Conditions
Prostate CancerRenal Cancer
Interventions
DRUG

[68Ga]P16-093

Imaging by Positron Emission Tomography after iv injection of \[68Ga\]P16-093

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Five Eleven Pharma, Inc.

INDUSTRY

NCT03073395 - Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer | Biotech Hunter | Biotech Hunter